… ProQR Prices Approximately $20 Million Underwritten Public … LEIDEN, The Netherlands, Nov. 14, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical … $3.25 per share. All of the shares are being offered by ProQR. In addition, in the public offering, ProQR has …
… ProQR Announces Webcast of Presentation at the Upcoming HC … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … will be available from the “Investors & Media” section of ProQR’s website under “ Events ” beginning on September 11, …
… ProQR Announces Last Patient Has Completed 12 Month Visit in … & CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … Daniel A. de Boer, Founder and Chief Executive Officer of ProQR. “Based on this event, we now anticipate sharing the …
… ProQR Receives Orphan Drug Designation from EMA for Drug … QR-313 for Dystrophic Epidermolysis Bullosa Key Updates ProQR’s drug candidate, QR-313 for dystrophic epidermolysis …
LEIDEN, the Netherlands, Sept. 14, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that PQ-010-002 is open for enrollment.
… ProQR Receives € 4.7 million in Innovation Credit from Dutch … CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … or the clinical development of a medicine or device. ProQR was awarded an Innovation credit for the QR-110 …
… ProQR Announces Presentation on QR-421a Program in … and CAMBRIDGE, Mass., July 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … delivered by Dr. Aniz Girach, MD, chief medical officer of ProQR, on QR-421a for Usher Syndrome during the USH2019 …
… ProQR Receives Rare Pediatric Disease Designation from FDA … & CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … children,” said Daniel de Boer, chief executive officer of ProQR. “This designation for sepofarsen underscores the …
LEIDEN, the Netherlands, March 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congenital amau